3.1 Clinical data
The demographic and clinical data of 273 patients post all-HSCT are
listed in Table 1. The average patient age at the time of the transplant
was 29.71 years-old. The M:F sex ratio was 171 (62.6%):102 (37.4%).
Acute myeloid leukemia, affecting 156 (57.1%) patients, acute lymphoid
leukemia, affecting 63 (23.1%) patients, and myelodysplastic syndrome,
affecting 33 (11.9%) patients, were the most frequently found diseases.
Among the patients, 254 had a standard risk status, and 19 had a
high-risk status. At the time of allo-HSCT, 256 patients were in
complete remission (CR), 2 were in partial remission, and 10 had disease
activity. All patients received peripheral blood as well as bone marrow
cells as their source of hematopoietic stem cells. Only 60 (22.0%)
samples were HLA-matched from their relatives. A total of 146 (53.5%)
patients developed acute GVHD, and 54 (19.8%) patients were found to
have a chronic form. As of April 2020, fifty (18.3%) had relapsed,
forty-three (15.8%) finally developed transplantation-related
mortality, and 188 (67.8%) remained alive. The median follow-up time
was 1799 days. The overall survival rate at five years was 32.2%,
whereas the leukemia-free survival rate was 32.7%.